治疗寻常痤疮新药:clascoterone  

A new drug in treatment of acne vulgaris: clascoterone

作　　者：孙韬华[1] 付婷[2] 刘杰[2] SUN Tao-hua;FU Ting;LIU Jie(Department of Drug Clinical Trials,Qingdao Municipal Hospital,Qingdao SHANDONG 266011,China;Department of Pharmacy,Qingdao Municipal Hospital,Qingdao SHANDONG 266011,China)

机构地区：[1]青岛市市立医院药物临床试验研究科,山东青岛266011 [2]青岛市市立医院药学部,山东青岛266011

出　　处：《中国新药与临床杂志》2021年第9期630-633,共4页Chinese Journal of New Drugs and Clinical Remedies

基　　金：青岛市2018年度医药科研指导计划(2018-WJZD010)。

摘　　要：clascoterone是一种雄激素受体抑制剂,由意大利Cassiopea S.p.A.公司研发。clascoterone乳膏于2020年8月获美国食品和药物管理局批准,用于12岁及以上寻常痤疮患者的局部治疗。clascoterone具有较强的局部抗雄激素丙酸睾酮的作用,不表现系统性抗雄激素作用。1%clascoterone乳膏安全性与乳膏基质相似,常见的局部皮肤反应包括红斑/潮红、脱屑/干燥、皮肤瘙痒等。Clascoterone is an androgen receptor inhibitor that developed by Italian Cassiopea S.p.A. In August 2020, clascoterone cream was approved by the U.S. Food and Drug Adiministration for the topical treatment of acne vulgaris in patients 12 years of age and older. Clascoterone endowed with strong local antiandrogenic activity against testosterone propionate,while absence of systemic antiandrogenic effects. Clascoterone cream 1% has been demonstrated a similar safety profile to that of vehicle, and common local skin reactions are erythema/redness, scaling/dryness, pruritus, and so on.

关 键 词：clascoterone 寻常痤疮 雄激素受体拮抗剂 

分 类 号：R977[医药卫生—药品]